| 4.4 0.2 (4.76%) | 05-23 13:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.54 | 1-year : | 6.48 |
| Resists | First : | 4.75 | Second : | 5.54 |
| Pivot price | 4.33 | |||
| Supports | First : | 4.16 | Second : | 3.79 |
| MAs | MA(5) : | 4.4 |
MA(20) : | 4.33 |
| MA(100) : | 5.52  |
MA(250) : | 8.02 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.1 | D(3) : | 63.1 |
| RSI | RSI(14): 51.7 | |||
| 52-week | High : | 11.8 | Low : | 3.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDRX ] has closed below upper band by 35.8%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.43 | 4.43 - 4.44 |
| Low: | 4.15 - 4.17 | 4.17 - 4.19 |
| Close: | 4.36 - 4.4 | 4.4 - 4.43 |
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Tue, 13 May 2025
Veradigm (MDRX) Leverages AI to Enhance Real-World Evidence for GLP-1 Agonists | MDRX Stock News - GuruFocus
Thu, 20 Mar 2025
Customer Attrition, Project Delays Dinged Veradigm Revenues in ’24 - Healthcare Innovation
Tue, 18 Mar 2025
Veradigm updates shareholder rights agreement - Investing.com
Tue, 18 Mar 2025
Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership - Yahoo Finance
Thu, 20 Feb 2025
Veradigm Amends and Extends Stockholder Rights Plan - Business Wire
Fri, 31 Jan 2025
Veradigm Eyes Operational Improvements After Not Finding a Buyer - Healthcare Innovation
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 108 (M) |
| Shares Float | 108 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 17.2 (%) |
| Shares Short | 8,130 (K) |
| Shares Short P.Month | 9,430 (K) |
| EPS | 0.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.77 |
| Profit Margin | 3.9 % |
| Operating Margin | 16.5 % |
| Return on Assets (ttm) | 2.1 % |
| Return on Equity (ttm) | 8.9 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.21 |
| EBITDA (p.s.) | 1.07 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 161 (M) |
| Levered Free Cash Flow | 156 (M) |
| PE Ratio | 5.11 |
| PEG Ratio | -0.7 |
| Price to Book value | 0.4 |
| Price to Sales | 0.3 |
| Price to Cash Flow | 2.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|